Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

BACKGROUND: Despite the reported efficacy of osimertinib, central nervous system (CNS) progression is still frequent in EGFR-mutated NSCLC. This study aimed to reveal site-specific resistant mechanisms to osimertinib and investigate subsequent treatments for leptomeningeal metastases (LM). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Mei-Mei, Li, Yang-Si, Tu, Hai-Yan, Sun, Hao, Yin, Kai, Jiang, Ben-Yuan, Yang, Jin-Ji, Zhang, Xu-Chao, Zhou, Qing, Xu, Chong-Rui, Wang, Zhen, Chen, Hua-Jun, Zhou, De-Xiang, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150343/
https://www.ncbi.nlm.nih.gov/pubmed/35644609
http://dx.doi.org/10.1186/s12916-022-02387-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150343/
https://www.ncbi.nlm.nih.gov/pubmed/35644609
http://dx.doi.org/10.1186/s12916-022-02387-0

Ejemplares similares